Back to discover
Disease

Hypoparathyroidism

Late-stage therapeutic developmentEmerging research
MeSHHypoparathyroidism
1
Publications
18
Clinical trials
2025
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 4 clinical trials expected to report results, the earliest in Q2 2027.
  • Active recent publication activity, including 1 notable finding.
  • 1 safety action from EMA issued.
Upcoming Milestones
Major developments
Major safety communicationHigh impact
Market withdrawal — Parathyroid Hormone
Natpar is indicated as adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.2026-07-01
Upcoming trial readoutImportant
An Expanded Cohort Study on the Safety and Efficacy of mRNA Nucleic Acid Drug XH-02 in Treating Adult Hypoparathyroidism
Results expected Q2 20302026-05-18
Major trial resultsImportant
Phase 2 Study of the PTH-Independent Effects of Encaleret on Mineral Homeostasis in Subjects With Post-Surgical Hypoparathyroidism (PSH)
Results posted2026-03-11
Research Highlights1View
Clinical Milestones7View
Results posted 1
Results expected 4
Recently completed 2
Regulatory Updates1View
  • 2026-07-01Market withdrawal — Parathyroid HormoneNatpar is indicated as adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.
Activity timeline9

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Palopegteriparatideapproved

Approval — Yorvipath is a parathyroid hormone (PTH) replacement therapy indicated for the treatment… (2023)

Parathyroid Hormoneapproved

Approval — Natpar is indicated as adjunctive treatment of adult patients with chronic hypoparathyroi… (2017)

Clinical trials

13 sponsors · 2 new · 2 completed in the last 12 months (net +2)

The current development programme across all trial phases.

Clinical programme
18
All trials
6
Active
8
Late-stage
6
Completed
Late-stage studies

Treatment With Indapamide in Patients With Post-Surgical Hypoparathyroidism

Phase 4 · Recruiting · Lars Rejnmark

CALCIUM CITRATE vs CALCIUM CARBONATE FOR THE MANAGEMENT OF CHRONIC HYPOPARATHYROIDISM

Phase 4 · Completed · Campus Bio-Medico University

PaTHway CHINA TRIAL: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism

Phase 3 · Completed · Visen Pharmaceuticals (Shanghai) Co., Ltd.

A Phase 4, Open-Label, Single-Center Clinical Study of Extended Use of rhPTH(1-84) in Hypoparathyroidism

Phase 4 · Completed · Shire

A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)]

Phase 4 · Completed · Shire

A Phase 3, Open-label Clinical Study of rhPTH(1-84) Treatment in Japanese Subjects With Chronic Hypoparathyroidism

Phase 3 · Withdrawn · Shire
Recruiting

Treatment With Indapamide in Patients With Post-Surgical Hypoparathyroidism

Phase 4 · Recruiting · Lars Rejnmark

An Expanded Cohort Study on the Safety and Efficacy of mRNA Nucleic Acid Drug XH-02 in Treating Adult Hypoparathyroidism

Phase 2 · Recruiting · Peking Union Medical College Hospital

PRESS -PAR: Early Detection and PREvention of Symptomatic postSurgical hypoPARathyroidism After Thyroid Surgery"

N/A · Recruiting · Nicolas Schlegel

A Pilot Study of Calcium Replacement Therapy in Postoperative Hypoparathyroidism

N/A · Recruiting · Tartu University Hospital

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Trial Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults With Hypoparathyroidism

Phase 2 · Recruiting · Extend Biosciences Inc.
Recently completed

Phase 2 Study of the PTH-Independent Effects of Encaleret on Mineral Homeostasis in Subjects With Post-Surgical Hypoparathyroidism (PSH)

Phase 2 · Completed · National Institute of Dental and Craniofacial Research (NIDCR)

PaTHway CHINA TRIAL: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism

Phase 3 · Completed · Visen Pharmaceuticals (Shanghai) Co., Ltd.

A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)]

Phase 4 · Completed · Shire

A Randomized Crossover TrIal to Compare Recombinant Human rhPTH(1-34) to the ASsociation Alfacalcidol/Hydrochlorothiazide in the Treatment of Severe Primary Hypoparathyroidism

Phase 2 · Completed · Assistance Publique - Hôpitaux de Paris

CALCIUM CITRATE vs CALCIUM CARBONATE FOR THE MANAGEMENT OF CHRONIC HYPOPARATHYROIDISM

Phase 4 · Completed · Campus Bio-Medico University

A Phase 4, Open-Label, Single-Center Clinical Study of Extended Use of rhPTH(1-84) in Hypoparathyroidism

Phase 4 · Completed · Shire

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2023emaApproval — Palopegteriparatide· Yorvipath is a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism source ↗
2017emaApproval — Parathyroid Hormone· Natpar is indicated as adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone. source ↗
Safety updates
2026emaMarket withdrawal — Parathyroid Hormone· Natpar is indicated as adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Major themes2
  • Endocrinology1
  • Hypoparathyroidism1
Leading journals1
  • European journal of endocrinology1
Leading researchers8
  • Bollerslev J1
  • Buch O1
  • Cardoso LM1
  • Dekkers OM1
  • Gittoes N1
  • Houillier P1
  • Makay O1
  • Marcocci C1
Affiliations (unnormalised)6
  • Aarhus University Hospital1
  • and Institute for Research and Innovation in Health of the University of Porto1
  • Aristotle University1
  • Brigham and Women's Hospital and Harvard Medical School1
  • Centre de Recherche des Cordeliers1
  • Centre de Référence des Maladies Rares du Calcium et du Phosphate1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A condition caused by a deficiency of PARATHYROID HORMONE (or PTH). It is characterized by HYPOCALCEMIA and hyperphosphatemia. Hypocalcemia leads to TETANY. The acquired form is due to removal or injuries to the PARATHYROID GLANDS. The congenital form is due to mutations of genes, such as TBX1; (see DIGEORGE SYNDROME); CASR encoding CALCIUM-SENSING RECEPTOR; or PTH encoding parathyroid hormone.

Identifiers
MeSHHypoparathyroidism
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.